Home/Pipeline/BDT272

BDT272

Neuropathic Pain

PreclinicalActive (In-licensed)

Key Facts

Indication

Neuropathic Pain

Phase

Preclinical

Status

Active (In-licensed)

Company

KYORIN Pharmaceutical

About KYORIN Pharmaceutical

KYORIN Pharmaceutical is a publicly listed Japanese pharmaceutical leader with a mission to contribute to people's health by addressing unmet medical needs. Founded in 1923 and publicly listed in 1999, the company has achieved significant scale with a market valuation of ~$94.8B, built on a foundation of established products in respiratory and urology. Its current strategy, outlined in the 'Vision 110' long-term plan, focuses on transforming its business structure to become a core innovator in new pharmaceuticals while expanding its healthcare portfolio.

View full company profile

Therapeutic Areas

Respiratory Urology Otolaryngology Infectious Disease Pain

Other Neuropathic Pain Drugs

Drug	Company	Phase	Status
NTRX-07	NeuroTherapia	Pre-clinical	Active
Neuropathic Pain Model Service	NeuroProof	Pre-clinical	Active
Sana Device for Neuropathic Pain	Sana Health	Pivotal Trial Completed	Active
Neuropathic Pain Program	VersaPeutics	Preclinical	Active
Cerebro Platform for Pain	Vonova.io	Pre-clinical	Active
ZYNPN	Zyneyro	Pre-clinical	Active
XT-150 (Preclinical)	Xalud Therapeutics	Preclinical	Active
ONO-2910	Ono Pharmaceutical	Phase 2	Active
VX-548	Vertex Pharmaceuticals	Phase 2	Active
HSK16149	Haisco Pharmaceutical Group	Phase III	Active
GRC-301	Grace Therapeutics	Preclinical	Candidate optimization